Led · Series G · Nov 2025

Distalmotion develops and commercializes the DEXTER robotic surgery system, designed to bring the benefits of robotics to outpatient settings. The platform has been adopted in clinical practice across Europe and the United States, treating more than 3,000 patients to date. In the U.S., DEXTER holds FDA clearance for adult inguinal hernia repair, cholecystectomy, and benign hysterectomy. The company positions its technology as a cost-effective, versatile option aimed at expanding robotic surgery beyond large tertiary hospitals. Following a $150 million Series G round in 2025, Distalmotion continues to invest in scaling operations and advancing product development. The latest strategic backing from Johnson & Johnson Innovation – JJDC is expected to accelerate these growth initiatives. Distalmotion maintains its headquarters in Lausanne, Switzerland, with an additional office in Cleveland, Ohio. No revenue figures were disclosed in the article, but the patient count underscores growing clinical adoption.

Participated · Series D · Jun 2023

Augmedics develops an AR-based navigation platform (branded Xvision) combining custom hardware and software to display digitized CT scans from a surgeon’s perspective. Its system, FDA-cleared in 2019 and commercially deployed in 2020, has been used in over 4,000 procedures and is installed in more than 70 U.S. hospitals. The platform can replace fluoroscopy in some non-invasive procedures and provides continuous intraoperative spine visualization in more invasive operations. The company emphasizes purpose-built hardware optimized for surgical use rather than off-the-shelf AR gear. Management plans to use new funding to build the next generation of the platform and accelerate commercial development while remaining focused on spinal applications. It has also received inbound interest for extensions into other musculoskeletal and cranial procedures that use CT/MRI imaging. Augmedics develops the xvision Spine System, the first and only FDA‑cleared augmented reality surgical image guidance system that lets surgeons visualize 3D spinal anatomy and navigate instruments while looking directly at the patient. The company received FDA 510(k) clearance in December 2019 and began U.S. sales in the second half of 2020. By year-end 2020 the system had been used in over 250 spinal surgeries. Augmedics plans to commercialize more broadly across the U.S. and into OUS markets, pursue CE certification for Europe, develop next‑generation products, and expand to new indications. Financially, the company has raised $63 million to date following a recent $36 million Series C and an earlier $21 million Series B. Augmedics develops the xvision Spine (XVS), an augmented reality surgical image-guidance system that enables surgeons to visualize a patient’s 3D spinal anatomy during surgery. XVS is designed to let surgeons accurately navigate instruments and implants while looking directly at the patient rather than a remote screen. The company received FDA 510(k) clearance and launched XVS in the U.S. in December 2019. The system is being used in renowned hospitals and surgical centers in the U.S. In June 2020 Augmedics completed a $15M Series B round that included staff investment and SAFE conversions. Leadership cited in the article includes founder and CEO Nissan Elimelech and President and CCO Tim Murawski. Augmedics develops the ViZOR, an augmented-reality surgical visualization system that projects a 3D image of a patient’s spine onto a surgeon’s retina in real time using proprietary see-through AR optics. The ViZOR is intended initially for minimally invasive spine surgeries to reduce operative time, radiation exposure and unnecessary repeat operations or hospitalizations. Augmedics plans to complete R&D and conduct pre-clinical and clinical trials of The ViZOR, and to pursue 510(k) clearance from the U.S. FDA. Future product development includes integrating sensors to collect surgical data and applying deep learning to provide suggestions, alerts and other intraoperative assistance. The company has received industry honors and previously raised seed financing from the TerraLab incubator (an incubator of the Israeli Innovation Authority). Financially, it recently secured an $8.3 million Series A to advance regulatory and commercialization efforts.